Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pathogen Reduced Cryoprecipitated Fibrinogen
Therapeutic Area : Hematology
Study Phase : Phase IV
Recipient : Weill Medical College of Cornell University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Intercept Fibrinogen Complex (Pathogen Reduced Cryoprecipitated Fibrinogen) is a Microorganism drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypofibrinogenemia.
Product Name : Intercept Fibrinogen Complex
Product Type : Microorganism
Upfront Cash : Inapplicable
February 03, 2023
Lead Product(s) : Pathogen Reduced Cryoprecipitated Fibrinogen
Therapeutic Area : Hematology
Highest Development Status : Phase IV
Recipient : Weill Medical College of Cornell University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Undisclosed
Sponsor : US Department of Defense
Deal Size : $9.1 million
Deal Type : Funding
Details : Cerus’ LyoCryo, a pathogen reduced, lyophilized cryoprecipitate, is being designed for shelf stability, rapid availability, and portability, enabling administration to patients in remote environments with the aim of increasing survival from traumatic i...
Product Name : LyoCryo
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 02, 2022
Lead Product(s) : Pathogen Reduced Lyophilized Cryoprecipitate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Undisclosed
Sponsor : US Department of Defense
Deal Size : $9.1 million
Deal Type : Funding
Lead Product(s) : Pathogen-Reduced Plasma
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase IV
Recipient : Coalition for National Trauma Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Plasma Resuscitation Without Lung Injury
Details : Pathogen-Reduced Plasma is a Microorganism drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Burns.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
December 23, 2020
Lead Product(s) : Pathogen-Reduced Plasma
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Recipient : Coalition for National Trauma Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Intercept Treated Red Blood Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : BARDA
Deal Size : $214.0 million
Deal Type : Funding
Cerus Expands BARDA Funding by Additional $14M
Details : Funding boosts further evaluation of the INTERCEPT Blood System's effectiveness in inactivating SARS-CoV-2 in all three blood components beyond what has already been identified.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 20, 2020
Lead Product(s) : Intercept Treated Red Blood Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : BARDA
Deal Size : $214.0 million
Deal Type : Funding
Lead Product(s) : Autologous Apheresis Platelet Component
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study
Details : Autologous Apheresis Platelet Component is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 12, 2016
Lead Product(s) : Autologous Apheresis Platelet Component
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NONOXYNOL-9
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Intercept is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 08, 2014
Lead Product(s) : NONOXYNOL-9
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Intercept Plasma
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Intercept Plasma is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemorrhagic Fever, Ebola.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 20, 2014
Lead Product(s) : Intercept Plasma
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : S-303
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : S-303 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of beta-Thalassemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2012
Lead Product(s) : S-303
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : S303 RBCs
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : S303 RBCs is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 30, 2012
Lead Product(s) : S303 RBCs
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Red Blood Cell
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells
Details : Red Blood Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 22, 2012
Lead Product(s) : Red Blood Cell
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable